Research and Development of Proposal-Based Businesses, New Technologies and Emerging Technologies
First written in FY2016. 23 of 28 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2026.
115 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The R&D themes are broadly divided into "IT applications in the medical field," "IT applications in the industrial field," and "applications of generative AI."」
The company expanded its R&D from medical AI to applications in the industrial field and generative AI, and recorded R&D expenses of ¥121.681 million. Progress was also made in the operational deployment of an aircraft-engine internal inspection tool and the development and academic presentation of a multi-agent system using a large language model. - FY2026-H1RestatedAnnual report
「Total R&D expenses for the current interim consolidated period were ¥58,730 thousand.」
The company has continued its R&D activities and reported R&D expenses of ¥58.730 million for the interim consolidated accounting period. - FY2025AdvancedAnnual report
「In advanced technologies, the Company has conducted multiple joint research projects using deep learning with medical universities and medical institutions in ophthalmology and other medical fields, including 11 projects in the current consolidated fiscal year, and has presented the results at ophthalmological and information-processing conferences, including its first overseas conference.」
The Company conducted 11 joint research projects in medical AI during the fiscal year and expanded its conference presentations to include its first overseas conference. It is also advancing the application of large language models to software development and the clinical testing and commercialisation of research results. - FY2024AdvancedAnnual report
「The Company conducted 13 projects during the current consolidated fiscal year and presented the results at ophthalmological and information-processing conferences.」
In R&D, the Company conducted 13 joint research projects in medical AI and exhibited 3 demonstration systems at an equipment exhibition held alongside an ophthalmology conference. It also continued commercialising research results, including the development of an aircraft-engine internal inspection tool. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥40,174 thousand.」
The Company continued its R&D activities and reported R&D expenses of ¥40,174 thousand for the second quarter of the current consolidated cumulative period. - FY2023AdvancedAnnual report
「In advanced technologies, the Company has conducted multiple joint research projects using deep learning with medical universities and medical institutions in ophthalmology and other medical fields, including 9 projects in the current consolidated fiscal year, and has presented the results at ophthalmological and information-processing conferences.」
The Company conducted 9 joint research projects in medical AI and related fields during the fiscal year, and continued R&D aimed at conference presentations, demonstrations and commercialisation. R&D expenses were ¥93,960 thousand. - FY2023-Q2RestatedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥52,972 thousand.」
The Company continued its R&D activities and reported R&D expenses of ¥52,972 thousand for the second quarter of the current consolidated cumulative period. - FY2022-Q3AdvancedAnnual report
「Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥100,746 thousand. December 2021: ・Commenced joint research on embedded security with Nagoya University.」
The Company continued and expanded its R&D activities, recording R&D expenses of ¥100,746 thousand and commencing joint research on embedded security with Nagoya University. - FY2022-Q2AdvancedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥66,289 thousand.」
The Company continued its R&D activities and reported R&D expenses of ¥66,289 thousand for the second quarter of the current consolidated cumulative period. - FY2022-Q1AdvancedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥33,143 thousand.」
The Company continued its R&D activities and recorded R&D expenses of ¥33,143 thousand for the first quarter of the current consolidated cumulative period. - FY2021AdvancedAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥97,943 thousand.」
The Company continued R&D in medical AI and image processing and conducted 8 joint research projects with medical universities and medical institutions during the fiscal year. R&D expenses were ¥97,943 thousand. - FY2021-Q3AdvancedAnnual report
「November 2020: ・An employee of the Company gave a presentation at "Agile Japan 2020." Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥66,108 thousand.」
The Company gave an external presentation on agile development and recorded R&D expenses of ¥66,108 thousand for the third quarter of the current consolidated cumulative period. - FY2021-Q2AdvancedAnnual report
「May 2020: ・At a research meeting organised by the Institute of Electronics, Information and Communication Engineers, an employee of the Company presented a paper on "Applications of AI in Medical Imaging." Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥48,063 thousand.」
The Company presented a paper on applications of AI in medical imaging and recorded R&D expenses of ¥48,063 thousand for the second quarter of the current consolidated cumulative period. - FY2021-Q1AdvancedAnnual report
「At a research meeting organised by the Institute of Electronics, Information and Communication Engineers, an employee of the Company presented a paper on "Applications of AI in Medical Imaging." Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥24,262 thousand.」
The Company presented a paper on applications of AI in medical imaging and recorded R&D expenses of ¥24,262 thousand for the quarter. - FY2020AdvancedAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥89,608 thousand.」
The Company advanced joint research in medical AI and image analysis, publication of papers in international journals and applications to maintenance support for industrial equipment, and recorded R&D expenses of ¥89,608 thousand. - FY2020-Q3AdvancedAnnual report
「・The academic journal "BMJ Open (BMJ)" published a research paper on "Classification of Corneal Topography Images Using Machine Learning" by Kitasato University, Miyata Eye Hospital and the Cresco Technical Research Institute. Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥67,347 thousand.」
A paper on medical image research using machine learning was published, bringing R&D expenses for the cumulative period to ¥67,347 thousand. - FY2020-Q2AdvancedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥47,131 thousand.」
The Company continued its R&D activities and reported R&D expenses of ¥47,131 thousand for the second quarter of the current consolidated cumulative period. It also obtained a US patent related to machine learning and gave presentations at academic conferences. - FY2020-Q1AdvancedAnnual report
「・㈱ニデック adopted the results of the Company's research and development in medical image analysis in its "Image Filing Software NAVIS(R)-EX." ・The academic journal "Journal of Ophthalmology (Hindwai)" published a research paper by an employee of the Company on "Automatic Classification of Chorioretinal Diseases Using OCT and Machine Learning." Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥21,173 thousand.」
Research results in medical image analysis and machine learning led to product adoption and publication in an academic journal, and R&D expenses of ¥21,173 thousand were recorded. - FY2019AdvancedAnnual report
「In particular, the Company has conducted multiple joint deep-learning research projects with medical universities in the ophthalmology field and has registered, published and presented the results at ophthalmological and artificial intelligence conferences, as well as in international ophthalmology journals. Total R&D expenses for the current consolidated fiscal year were ¥94,284 thousand.」
The Company advanced the publication and presentation of results from joint deep-learning research with medical universities and recorded R&D expenses of ¥94,284 thousand. - FY2019-Q3AdvancedAnnual report
「August 2018: ・An employee of the Company gave a presentation at the Project Management Society's "2018 Autumn Research Conference." Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥69,638 thousand.」
The Company presented research on project management and continued its R&D activities. R&D expenses were reported at ¥69,638 thousand. - FY2019-Q2AdvancedAnnual report
「July 2018: ・The Company presented the results of joint research on classifying corneal topography images using machine learning at the Institute of Electronics, Information and Communication Engineers. Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥43,060 thousand.」
The Company presented the results of joint research using machine learning and continued its R&D activities. R&D expenses were ¥43,060 thousand. - FY2018AdvancedAnnual report
「Total R&D expenses for the current consolidated fiscal year were ¥92,730 thousand.」
The Company conducted research on machine learning, image processing, natural language processing, solution implementation, development standardisation and productivity improvement, and recorded R&D expenses of ¥92,730 thousand. - FY2018-Q3AdvancedAnnual report
「April 2017: ・An employee of the Company presented at the Project Management Society's "2017 Spring Research Conference." May 2017: ・An employee of the Company gave a presentation on "Agile Project Management" at PMI Japan Forum 2017. September 2017: ・An employee of the Company presented at the Project Management Society's "2017 Autumn Research Conference."」
The Company gave multiple presentations and conference talks on project management and agile project management. Total R&D expenses were reported at ¥68,793 thousand. - FY2018-Q2AdvancedAnnual report
「May 2017: ・An employee of the Company gave a presentation on "Agile Project Management" at PMI Japan Forum 2017. September 2017: ・An employee of the Company presented at the Project Management Society's "2017 Autumn Research Conference." Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥44,230 thousand.」
The Company gave presentations and conference talks on project management and continued its R&D activities. R&D expenses were reported at ¥44,230 thousand. - FY2018-Q1AdvancedAnnual report
「April 2017: ・The Technical Research Institute presented the results of fiscal 2016 at an open house. Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥21,282 thousand.」
The Technical Research Institute presented the previous fiscal year's results at an open house and continued its R&D activities. R&D expenses were reported at ¥21,282 thousand. - FY2017-Q3AdvancedAnnual report
「November 2016: Presented the results of joint research with Nagoya City University at a meeting of the Medical Imaging Study Group of the Institute of Electronics, Information and Communication Engineers. Presentation topic: “Using optical coherence tomography images and machine learning to identify eye diseases.”」
The Company reported a specific result of its R&D activities: a conference presentation of joint research using machine learning. - FY2017-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥21,787 thousand.」
The Company continued its R&D activities and reported R&D expenses of ¥21,787 thousand for the quarter. - FY2016First statedAnnual report
「Research and development themes are broadly classified into "research and development related to sales and solutions," "research and development related to new technologies" and "research and development related to development technologies."」
The research covered new technologies such as security, the Internet, wireless communications and cloud computing, sales methods and new solutions, and development standardisation, efficiency and quality improvement. R&D expenses were ¥94,175 thousand.